Interleukin 35 Polymorphisms Are Associated with Decreased Risk of Premature Coronary Artery Disease, Metabolic Parameters, and IL-35 Levels: The Genetics of Atherosclerotic Disease (GEA) Study

• Published in: Mediators of inflammation Vol. 2017; no. 2017; pp. 1 - 10
• Main Authors: Vargas-Alarcón, Gilberto, Posadas-Romero, Carlos, Rodríguez-Pérez, José Manuel, Villarreal-Molina, Teresa, López-Bautista, Fabiola, Angeles-Martinez, Javier, Pérez-Hernández, Nonanzit, Posadas-Sánchez, Rosalinda, Fragoso, José Manuel
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01-01-2017; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Acute coronary syndromes; Adult; Alzheimer's disease; Angina pectoris; Arthritis; Atherosclerosis; Atherosclerosis - genetics; Atherosclerosis - metabolism; Calcification; Cardiovascular disease; Complications and side effects; Coronary Artery Disease - genetics; Coronary Artery Disease - metabolism; Coronary heart disease; Coronary vessels; Cytokines; Development and progression; Female; Gene Frequency - genetics; Genes; Genetic aspects; Genetic polymorphisms; Genetic Predisposition to Disease - genetics; Genetics; Genomics; Genotype; Haplotypes - genetics; Health aspects; Heart attacks; Humans; Interleukins; Interleukins - genetics; Interleukins - metabolism; Male; Middle Aged; Physiological aspects; Polymorphism, Single Nucleotide - genetics; Risk Factors; Studies; Tuberculosis; Mexico
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2017/6012795

Interleukin 35 (IL-35) is a heterodimeric cytokine involved in the development of atherosclerosis. The aim of the present study was to establish if the polymorphisms of IL-12A and EBI3 genes that encode the IL-35 subunits are associated with the development of premature coronary artery disease (CAD) in Mexican individuals. The IL-12A and EBI3 polymorphisms were determined in 1162 patients with premature CAD and 873 controls. Under different models, the EBI3 rs428253 (OR = 0.831, P a d d = 0.036; OR = 0.614, P r e c = 0.033; OR = 0.591, P c o d 2 = 0.027) and IL-12A rs2243115 (OR = 0.674, P a d d = 0.010; OR = 0.676, P d o m = 0.014; OR = 0.698, P h e t = 0.027; OR = 0.694, P c o d 1 = 0.024) polymorphisms were associated with decreased risk of developing premature CAD. Some polymorphisms were associated with clinical and metabolic parameters. Significant different levels of IL-35 were observed in EBI3 rs4740 and rs4905 genotypes only in the group of healthy controls. In summary, our study suggests that the EBI3 and IL-12A polymorphisms play an important role in decreasing the risk of developing premature CAD; it also demonstrates the relationship of the EBI3 rs4740 and rs4905 genotypes with IL-35 levels in healthy individuals.